MicroRNA‑425 upregulation indicates better prognosis in younger acute myeloid leukemia patients undergoing chemotherapy

  • Authors:
    • Jilei Zhang
    • Jinlong Shi
    • Gaoqi Zhang
    • Xinpei Zhang
    • Xinrui Yang
    • Siyuan Yang
    • Jing Wang
    • Kai Hu
    • Xiaoyan Ke
    • Lin Fu
  • View Affiliations

  • Published online on: April 4, 2019     https://doi.org/10.3892/ol.2019.10217
  • Pages: 5793-5802
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate whether the expression levels of microRNA‑425 (miR‑425) were associated with the prognosis of acute myeloid leukemia (AML) in patients treated with chemotherapy or allogeneic hematopoietic stem cell transplantation (allo‑HSCT). A total of 162 AML patients were enrolled and divided into chemotherapy and allo‑HSCT groups. Next, the overall survival (OS) and event‑free survival (EFS) were compared between patients with high and low miR‑425 expression in each of the treatment groups. In the chemotherapy group, high miR‑425 expression was favorable for EFS (P=0.001) and OS (P=0.001) in younger patients (<60 years), whereas it had no effect on EFS and OS in older patients (≥60 years). In the allo‑HSCT group, there was no association between miR‑425 expression levels and clinical outcomes. Further analyses suggested that in the low miR‑425 expression group, EFS and OS were longer in patients treated with allo‑HSCT as compared with those treated with chemotherapy (both P<0.001), whereas no significant differences were observed in the high miR‑425 expression group. In conclusion, the current data indicated that miR‑425 is an independent favorable prognostic factor for younger AML patients undergoing chemotherapy, and its use may facilitate clinical decision‑making in selecting treatment for AML patients. Patients with low miR‑425 expression may benefit from allo‑HSCT, whereas allo‑HSCT did not appear to be beneficial in patients with high miR‑425 expression.
View Figures
View References

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Zhang, J., Shi, J., Zhang, G., Zhang, X., Yang, X., Yang, S. ... Fu, L. (2019). MicroRNA‑425 upregulation indicates better prognosis in younger acute myeloid leukemia patients undergoing chemotherapy. Oncology Letters, 17, 5793-5802. https://doi.org/10.3892/ol.2019.10217
MLA
Zhang, J., Shi, J., Zhang, G., Zhang, X., Yang, X., Yang, S., Wang, J., Hu, K., Ke, X., Fu, L."MicroRNA‑425 upregulation indicates better prognosis in younger acute myeloid leukemia patients undergoing chemotherapy". Oncology Letters 17.6 (2019): 5793-5802.
Chicago
Zhang, J., Shi, J., Zhang, G., Zhang, X., Yang, X., Yang, S., Wang, J., Hu, K., Ke, X., Fu, L."MicroRNA‑425 upregulation indicates better prognosis in younger acute myeloid leukemia patients undergoing chemotherapy". Oncology Letters 17, no. 6 (2019): 5793-5802. https://doi.org/10.3892/ol.2019.10217